JJDC helps cancer researcher Aduro close $55m series C

Jun 12, 2014 • Robert Lavine

Aduro Biotech has now raised $84m after securing Johnson & Johnson as a new investor alongside Morningside and several undisclosed backers.

Aduro Biotech, a US-based biotechnology company devising treatments for pancreatic cancer, closed a $55m series C round yesterday, with Johnson & Johnson Development Corporation (JJDC), the corporate venturing arm of pharmaceutical firm Johnson & Johnson, participating as a new investor.

Investment firm Morningside Group also took part in the round alongside undisclosed new and existing investors. Aduro said it has now raised $84m in equity funding since it was founded in 2000.

JJDC’s investment comes two weeks after Johnson &…

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

FUNDING ROUND DATA

Which corporates are backing which startups? Search our corporate deal database.

CVC DIRECTORY

Find details about global CVC units in the CVC Directory

SPECIAL REPORT

Bumpy road: Self-driving cars make a cautious comeback

Events

Webinar: Designing a winning CVC platform – Engagement, venture development, operations

Jan 15, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Jan 28 -
Jan 29, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)

Find out more All events

Events

GCVI Summit 2025

Mar 18 -
Mar 20, 2025
Monterey, CA (USA)

Find out more All events

Events

GCV Institute: CVC Investment Programs

Apr 8 -
Apr 10, 2025
Online

Find out more All events

Events

GCV Institute: Landing the Value of Corporate Venturing

May 1 -
May 6, 2025
Online

Find out more All events

Events

GCV Symposium 2025

Jun 17 -
Jun 19, 2025
London (UK)

Find out more All events

About us

GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.